{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:10:07Z","timestamp":1793815807693,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jcyt.2024.09.004","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T21:53:23Z","timestamp":1728078803000},"page":"181-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3130-5133","authenticated-orcid":false,"given":"Ridhima","family":"Vij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeonggeun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamchid","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.09.004_bib0001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2741\/S415","article-title":"Parkinson's disease: a review","volume":"6","author":"Beitz","year":"2014","journal-title":"Front Biosci (Schol Ed)"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0002","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMct1208070","article-title":"Deep-brain stimulation for Parkinson's disease","volume":"367","author":"Okun","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0003","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JPD-212976","article-title":"Monoamine Oxidase-B inhibitors for the treatment of Parkinson's disease: past, present, and future","volume":"12","author":"Tan","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0004","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00228-020-02961-6","article-title":"Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis","volume":"76","author":"Binde","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0005","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.3390\/ijms21218060","article-title":"Stem cell-based therapies for Parkinson disease","volume":"21","author":"Liu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0006","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1254\/jphs.14R10CP","article-title":"Therapeutic potential of human adipose-derived stem cells in neurological disorders","volume":"126","author":"Chang","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.retram.2016.10.007","article-title":"Mesenchymal stem cell therapy in Parkinson's disease animal models","volume":"65","author":"Gugliandolo","year":"2017","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0008","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.3390\/ijms24043888","article-title":"Adipose-derived mesenchymal stromal cells in basic research and clinical applications","volume":"24","author":"Czerwiec","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0009","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.3390\/ijms25115916","article-title":"Clinical applications of adipose-derived stem cell (ADSC) exosomes in tissue regeneration","volume":"25","author":"Papadopoulos","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0010","first-page":"102482","article-title":"Role of adipose mesenchymal stem cells and secretome in peripheral nerve regeneration","volume":"67","author":"Sumarwoto","year":"2021","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0011","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1177\/0963689718757408","article-title":"Adipose-derived stem cells stimulated with n-butylidenephthalide exhibit therapeutic effects in a mouse model of Parkinson\u2019s disease","volume":"27","author":"Chi","year":"2018","journal-title":"Cell Transplantation"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40035-021-00238-1","article-title":"Effectiveness and mechanisms of adipose-derived stem cell therapy in animal models of Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"10","author":"Li","year":"2021","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0013","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jcyt.2014.09.005","article-title":"Human adipose-derived mesenchymal stromal cells increase endogenous neurogenesis in the rat subventricular zone acutely after 6-hydroxydopamine lesioning","volume":"17","author":"Schwerk","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0014","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ane.13547","article-title":"Repeated infusion of autologous adipose tissue-derived stem cells for Parkinson's disease","volume":"145","author":"Shigematsu","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.expneurol.2013.03.016","article-title":"Mesenchymal stem cells and neuroregeneration in Parkinson's disease","volume":"247","author":"Glavaski-Joksimovic","year":"2013","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0016","first-page":"726","article-title":"Beyond statistical significance: clinical interpretation of rehabilitation research literature","volume":"9","author":"Page","year":"2014","journal-title":"Int J Sports Phys Ther"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0017","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.psychres.2018.10.069","article-title":"Enhancing the understanding of clinically meaningful results: a clinical research perspective","volume":"270","author":"Nordahl-Hansen","year":"2018","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0018","first-page":"467131","article-title":"Minimal clinically important difference in Parkinson\u2019s disease as assessed in pivotal trials of pramipexole extended release","volume":"2014","author":"Hauser","year":"2014","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0019","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/mds.23638","article-title":"Determination of minimal clinically important change in early and advanced Parkinson's disease","volume":"26","author":"Hauser","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000455863","article-title":"Changes in quality of life in Parkinson\u2019s disease: how large must they be to be relevant?","volume":"48","author":"Horv\u00e1th","year":"2017","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0021","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4103\/aian.aian_207_23","article-title":"Minimal clinically important difference (MCID) in patient-reported outcome measures for neurological conditions: review of concept and methods","volume":"26","author":"Mishra","year":"2023","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0022","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0023","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mdc3.12553","article-title":"Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson's progression markers initiative cohort","volume":"5","author":"Holden","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0024","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/mds.26960","article-title":"Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson\u2019s disease rating scale","volume":"32","author":"Horv\u00e1th","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0025","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the Motor Examination part of MDS-UPDRS","volume":"21","author":"Horv\u00e1th","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0026","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","article-title":"Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale","volume":"58","author":"Makkos","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0027","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1017\/S0033291720003700","article-title":"How much change is enough? Evidence from a longitudinal study on depression in UK primary care","volume":"52","author":"Kounali","year":"2022","journal-title":"Psychol Med"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0028","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.parkreldis.2004.07.007","article-title":"The Parkinson fatigue scale","volume":"11","author":"Brown","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0029","first-page":"88","article-title":"Evaluating the psychometric properties of the Persian version of Parkinson Fatigue Scale (PFS-16) in patients with Parkinson\u2019s disease","volume":"2","author":"Baghoori","year":"2017","journal-title":"J Clin Physiother Res"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mds.22989","article-title":"Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson\u2019s disease","volume":"25","author":"Friedman","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0031","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/WNL.0b013e318285c0ed","article-title":"Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications","volume":"80","author":"Storch","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0032","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s42234-020-00055-3","article-title":"Single arm prospective multicenter case series on the use of burst stimulation to improve pain and motor symptoms in Parkinson's disease","volume":"6","author":"Chakravarthy","year":"2020","journal-title":"Bioelectron Med"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0033","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jhsa.2022.03.009","article-title":"Establishing the minimal clinically important difference and substantial clinical benefit for the pain visual analog scale in a postoperative hand surgery population","volume":"47","author":"Randall","year":"2022","journal-title":"J Hand Surg Am"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0034","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/term.504","article-title":"Transplantation of porcine umbilical cord matrix mesenchymal stem cells in a mouse model of Parkinson\u2019s disease","volume":"7","author":"Kang","year":"2013","journal-title":"J Tissue Eng Regen Med"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0036","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3727\/096368912X640556","article-title":"Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a Parkinsonian model","volume":"21","author":"Park","year":"2012","journal-title":"Cell Transplant"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0037","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3727\/096368915X689938","article-title":"Combined MSC-secreted factors and neural stem cell transplantation promote functional recovery of PD rats","volume":"25","author":"Yao","year":"2016","journal-title":"Cell Transplant"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0038","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jocn.2020.09.001","article-title":"Sustained clinical improvement of Parkinson's disease in two patients with facially-transplanted adipose-derived stromal vascular fraction cells","volume":"81","author":"Carstens","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0039","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trsl.2009.07.006","article-title":"Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson\u2019s disease","volume":"155","author":"Venkataramana","year":"2010","journal-title":"Transl Res"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0040","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00415-019-09348-3","article-title":"Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort","volume":"266","author":"Regnault","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0041","first-page":"635","article-title":"Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus","volume":"35","author":"Goligher","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0042","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jclinepi.2007.08.016","article-title":"Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis","volume":"61","author":"Pouchot","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jcyt.2024.09.004_bib0043","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J Rheumatol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924008855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924008855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T17:57:51Z","timestamp":1737309471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924008855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1465324924008855"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.09.004","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}